

Near-infrared fluorescence molecular endoscopy detects dysplastic oesophageal lesions using topical and systemic tracer of vascular endothelial growth factor A

Wouter B Nagengast,¹ Elmire Hartmans,¹ Pilar B Garcia-Allende,² Frans T M Peters,¹ Matthijs D Linssen,^{1,3} Maximilian Koch,² Marjory Koller,⁴ Jolien J J Tjalma,¹ Arend Karrenbeld,⁵ Annelies Jorritsma-Smit,³ Jan H Kleibeuker,¹ Gooitzen M van Dam,^{4,6} Vasilis Ntziachristos²

► Additional material is published online only. To view please visit the journal online (http://dx.doi.org/10.1136/ gutjnl-2017-314953).

For numbered affiliations see end of article.

Correspondence to

Dr Wouter B Nagengast, Department of Gastroenterology and Hepatology, University of Groningen, University Medical Center, Groningen, The Netherlands; w.b.nagengast@ umcg.nl

WBN and EH contributed equally.

Received 4 August 2017 Revised 25 October 2017 Accepted 16 November 2017 Published Online First 15 December 2017



To cite: Nagengast WB, Hartmans E, Garcia-Allende PB, *et al. Gut* 2019;**68**:7–10. The incidence of oesophageal adenocarcinoma (EAC) is steeply rising. Early lesion detection is a critical factor for improving disease prognosis. We developed and investigated wide-field near-infrared fluorescence molecular endoscopy (NIR-FME), using systemic and topical administration of a fluorescence-labelled antibody against vascular endothelial growth factor (VEGFA). Fourteen patients with Barrett's oesophagus (BE) underwent endoscopic mucosal resection (EMR) combined with NIR-MFE. From a total of 20 confirmed aberrant lesions identified with NIR-FME, 4 lesions were missed by high-definition (HD) narrowband imaging (NBI) and white-light endoscopy (WLE). This overall 25% detection enhancement advocates NIR-FME as a promising 'red-flag' technique for improving early oesophageal lesion detection. ClinicalTrials.gov ID NCT02129933.

IN MORE DETAIL

MESSAGE

Worldwide, >450000 people are diagnosed with oesophageal cancer each year. In the western world, at least 80% of these cancers concern EAC.¹⁻⁴ Latestage disease detection challenges the efficacy of therapies, resulting in 400000 deaths each year. Therefore, there is a pressing need for new endoscopic techniques that enable early EAC detection. Endoscopic imaging of targeted fluorescent agents directed against cancer-specific cellular and subcellular moieties, that is, fluorescence molecular endoscopy (FME), has been heralded as a novel method for oesophageal dysplasia and cancer detection.⁵ FME enables surface and subsurface visualisation of cancer-specific pathophysiology, going beyond the surface-only morphology and tissue discolourations visible with HD-WLE.^{6–10}

In this study, we investigated for the first time real-time NIR-FME of EAC and dysplasia. A pilot study in patients with BE was based on a novel custom-built NIR fluorescence endoscope, paired to a HD-WL clinical scope (online supplementary figure 1) and employed the anti-VEGFA antibody bevacizumab, labelled with the NIR-fluorescent 800CW. The potential of VEGFA as an early discriminating target in BE was first confirmed by immunohistochemistry, demonstrating that all dysplastic tissues expressed VEGFA (online supplementary figure 2).

The study furthermore compared systemic versus topical tracer administration during clinical inspection of the oesophagus in 14 patients with BE, scheduled to undergo an EMR of previously diagnosed lesions (figure 1A). Five patients received an intravenous bolus of bevacizumab 800CW, 2 days prior to the NIR-FME procedure (4.5 mg, bolus injection). The other nine patients received topical administration of the tracer, by spraying bevacizumab 800CW on the luminal surface (100 μ g/mL per cm BE) immediately prior to wide-field NIR-FME. The online supplementary table 1 summarises study subjects and lesion characteristics.

In the systemic tracer administration subgroup, four out of five EAC lesions were well identified by wide-field NIR-FME inspection (figure 1B). The fifth lesion had its origin in the gastric cardia and was only visible in endoscopic U-turn. Due to the bending restrictions of the current fibre bundle, this lesion was not accessible for the custom-built NIR-FME endoscope employed in the study. Nevertheless, this fifth lesion demontrated high fluorescent tracer uptake ex vivo (online supplementary figure 3). In the topical tracer group, NIR-FME visualised all (12/12) dysplastic and neoplastic lesions, exactly matching the contour of the lesion during HD-WLE inspection, including a carcinomatous area that was only identified by random biopsies (figure 1C; total of 9 patients: 1/9 no focal lesion on HD-WLE/NBI inspection, 5/9 one focal lesion and 3/9 patients two focal lesions). In addition, topical tracer-based NIR-FME identified four additional dysplastic lesions, which were not identified by HD-WLE and NBI inspection (+33%, figure 1D). Moreover, the topical administration led to a slightly higher in vivo tumour-to-background ratio (TBR) of 4.30±0.41, compared with the systemic administration (online supplementary figure 4).

COMMENTS

The known limitations of clinically available endoscopes initiated a search for novel imaging



7



Figure 1 Real-time VEGFA-targeted NIR-FME. (A) Schematic overview and timeline of the two NIR-FME approaches (n=14). (B) Examples of the systemic tracer based, and (C) the topical tracer results, summarising that all lesions could be visualised with NIR-FME, including one EAC area which was not visible during HD inspection (displayed in C—first row). (D) Additionally identified dysplastic areas during NIR-FME, which were missed during HD-NBI inspection. All fluorescence signals presented here are uncorrected; overlay images display the high intensities only. EAC, oesophageal adenocarcinoma; HD, high-definition; HGD, high-grade dysplasia; LGD, low-grade dysplasia; NIR-FME, near-infrared fluorescence molecular endoscopy; NBI, narrow-band imaging; VEGFA, antibody against vascular endothelial growth factor.

techniques that allow improved detection of early oesophageal lesions. FME is heralded as a highly promising method for detecting dysplastic and neoplastic lesions. To date, three studies—one ex vivo study and two clinical trials—have been reported on FME in EAC^{5 11 12}; however, none of these studies showed real-time wide-field inspection of the oesophageal lumen. Compared with previous studies, the NIR-FME technique offers three advantages. First, the system design enables concurrent use of HD-WLE and sensitive functional fluorescence detection of lesions. Second, NIR-FME offers a 'red-flag' surveillance method that inspects at least four orders of magnitude higher fields of view compared with confocal laser endomicroscopy, an ability that can be further exploited to guide biopsy. Moreover, the switch from visible wavelengths in previous studies⁵ ¹¹ ¹² to the NIR leads to fluorescence detection with superior sensitivity, allowing for the first time real-time in vivo WLE and concurrent FME imaging. Finally, NIR wavelengths are less subjected to interference by haemoglobin absorption, autofluorescence signals and tissue scattering.¹³

The endoscopic fluorescence images, concurrently recorded with HD-WLE in vivo, matched the focal areas as defined with HD-WLE. In addition, ex vivo fluorescence imaging precisely matched the histology findings (figure 2A; details online). The areas that exhibited increased fluorescence—including the areas



Figure 2 Ex vivo VEGFA and fluorescent signal analyses of study subjects. (A) Boxplot presenting IHC results (H-score: median, 10–90 percentile); a significant difference in VEGFA staining intensities is observed between the dysplastic and benign tissue sites (**P<0.0001). (B) Tukey boxplot presenting the MFIs observed (mean value in bold) (*P<0.05). (C) Fluorescence scan and 3D surface plot demonstrating that the tracer is located in the EAC area and (D) fluorescence microscopy of this same area showing NIR fluorescence within the stromal tissue, between the tumour ducts. (E) Fluorescence scan demonstrating that the tracer is located in tumour blood vessels and tumour ducts. EAC, oesophageal adenocarcinoma; EMR, endoscopic mucosal resection; HE, haematoxylin and eosin; HGD, high-grade dysplasia; IHC, immunohistochemistry; IM, intestinal metaplasia; MFI, mean fluorescence intensities; NIR, near-infrared; VEGFA, antibody against vascular endothelial growth factor.

that were not identified as dysplastic by HD-WLE—were identified as aberrant by histopathology (true positives; figure 1B–D). Random biopsies, which contained benign mucosal lining, did not exhibit fluorescence (true negatives). Moreover, we did not observe fluorescence at the submucosal layer or at the resection margin following EMR, which was confirmed by histopathology; all EMR procedures were radical (R0) resections, as evinced by follow-up endoscopy.

In addition, fluorescence signals recorded ex vivo were congruent with high intracellular VEGFA stainings (figure 2A). This finding is consistent with previous observations, linking (labelled)-bevacizumab uptake to areas of elevated VEGFA.¹⁴⁻¹⁶ Furthermore, labelled bevacizumab has been shown trapped in the extracellular matrix, when bound to the large VEGFA

isoforms that are attached to the cell surface.^{14 17} This reported high VEGFA expression in dysplastic and neoplastic areas can be explained by the role of VEGFA in neovascularisation and has been reported to be elevated already in BE dysplasia.¹⁷⁻²²

Ex vivo assessment of the specimen obtained from the systemic tracer group showed significant differences in mean fluorescence intensity between the aberrant areas (EAC/high-grade dysplasia) and the benign mucosal lining, resulting in a favourable ex vivo TBR of 16.7 (figure 2B, P value <0.001). Furthermore, ex vivo NIR microscopy of the formalin-fixed and paraffin-embedded slices confirmed the presence of NIR fluorescence in EAC areas (figure 2C), tumour stromal tissue and surrounding tumour blood vessels (figure 2D-E), while low fluorescence was seen at the margin containing normal Barrett lining. Likewise,

Endoscopy news

macroscopic ex vivo imaging of the formalin-fixed specimens that received topical tracer administration exhibited NIR fluorescence at dysplastic and EAC sites (online supplementary figure 5), though typically at lower intensity compared with the samples from the group receiving systemic administration due to agent washout during the fixation process.

We observed adverse events in 4/14 patients, all known complications of the EMR procedure: bleeding (n=2), nausea/headache (n=1) and fever (n=1). Most likely these events are not tracer-related as only 1%–1.5% of the therapeutic bevacizumab dose was used (4.5 mg vs 5 mg/kg). Our study has several limitations. First, our NIR-FME system uses a sensitive fibre bundle for fluorescence imaging, but an integrated NIR imaging system in a standard HD endoscope would most likely simplify the procedure. Second, our patient sample is small and powered as phase I study for safety, therefore, a randomised phase II or III trial is required to verify the additive role of NIR-FME in BE surveillance.

In conclusion, this work demonstrates that concurrent use of VEGFA-guided NIR-FME and HD-WLE, following topical or systemic tracer administration, can be used to detect dysplastic and early EAC lesions in patients with BE. Our in vivo results show that even flat and difficult to distinguish lesions were identifiable with NIR-FME. Moreover, the topical tracer approach was able to improve early lesion detection by \sim 33% compared with HD-WL/NBI endoscopy.

Author affiliations

¹Department of Gastroenterology and Hepatology, University of Groningen, University Medical Center, Groningen, The Netherlands

²Chair for Biological Imaging and Institute for Biological and Medical Imaging, Technical University of Munich and Helmholtz Centre Munich, Munich, Germany ³Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center, Groningen, The Netherlands

⁴Department of Surgery, University of Groningen, University Medical Center, Groningen, The Netherlands

⁵Department of Pathology, University of Groningen, University MedicalCenter, Groningen, The Netherlands

⁶Department of Nuclear Medicine & Molecular Imaging and Intensive Care, University of Groningen, University Medical Center, Groningen, The Netherlands

Acknowledgements The authors would like to thank research analyst W Boersma-van Ek for her assistance in the laboratory, especially for her contribution in the IHC staining and scoring process. Furthermore, they would like to thank Prof JJGHM Bergman for carefully reading the manuscript.

Contributors WBN, EH, FTMP and JHK: involved in the clinical study design. WBN, EH, JJJT, MK and FTMP: enrolled patients, performed endoscopic procedures and/or acquired specimens. PBG-A, WBN and VN: involved in the development of the NIR-MFE system. MDL and AJS: involved in the GMP tracer production. AK: involved in pathological assessment and analyses of the ex vivo data. WBN and EH: drafted the manuscript. FTMP, GMvD and VN: critically revised drafts of the manuscript. WBN, GMvD and VN: designed the research concept and/or supervised all aspects of the final manuscript.

Funding This work was financially supported by the Dutch Cancer Society: KWF Kankerbestrijding (RUG 2012-5416), The DFG Leibnitz Proze Award and via an unrestricted research grant for molecular imaging from SurgVision BV (The Netherlands).

Competing interests WBN and GMvD received an unrestricted research grant for molecular imaging development from SurgVision BV (the Netherlands). GMvD and VN are in the scientific advisory board of Surgvision BV. The other authors have no conflicts to declare.

Patient consent Obtained.

Ethics approval METc Groningen.

Provenance and peer review Not commissioned; internally peer reviewed.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/ licenses/by-nc/4.0/

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2019. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

REFERENCES

- Jankowski M, Wani S. Diagnostic and management implications of basic science advances in barrett's esophagus. *Curr Treat Options Gastroenterol* 2015;13:16–29.
- 2 Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013;49:1374–403.
- 3 Pera M, Manterola C, Vidal O, et al. Epidemiology of esophageal adenocarcinoma. J Surg Oncol 2005;92:151–9.
- 4 Vial M, Grande L, Pera M. Epidemiology of adenocarcinoma of the esophagus, gastric cardia, and upper gastric third. Recent Results Cancer Research. 182. Berlin, Heidelberg: Springer Berlin Heidelberg, 2010:1–17.
- 5 Bird-Lieberman EL, Neves AA, Lao-Sirieix P, et al. Molecular imaging using fluorescent lectins permits rapid endoscopic identification of dysplasia in Barrett's esophagus. Nat Med 2012;18:315–21.
- 6 Joshi BP, Wang TD. Gastrointestinal imaging in 2015: Emerging trends in endoscopic imaging. Nat Rev Gastroenterol Hepatol 2016;13:72–3.
- 7 Atreya R, Goetz M. Molecular imaging in gastroenterology. Nat Rev Gastroenterol Hepatol 2013;10:704–12.
- 8 Goetz M, Wang TD. Molecular imaging in gastrointestinal endoscopy. *Gastroenterology* 2010;138:828–33.
- 9 Hoetker MS, Goetz M. Molecular imaging in endoscopy. United European Gastroenterol J 2013;1:84–92. SAGE Publications.
- 10 Bézière N, Ntziachristos V. Optoacoustic imaging: an emerging modality for the gastrointestinal tract. *Gastroenterology* 2011;141:1979–85.
- 11 Sturm MB, Joshi BP, Lu S, et al. Targeted imaging of esophageal neoplasia with a fluorescently labeled peptide: first-in-human results. Sci Transl Med 2013;5:184ra61–1.
- 12 Joshi BP, Duan X, Kwon RS, et al. Multimodal endoscope can quantify wide-field fluorescence detection of Barrett's neoplasia. Endoscopy 2016;48.
- 13 Hilderbrand SA, Weissleder R. Near-infrared fluorescence: application to in vivo molecular imaging. *Curr Opin Chem Biol* 2010;14:71–9.
- 14 Stollman TH, Scheer MG, Leenders WP, et al. Specific imaging of VEGF-A expression with radiolabeled anti-VEGF monoclonal antibody. Int J Cancer 2008;122:2310–4.
- 15 Gaykema SB, Brouwers AH, Lub-de Hooge MN, et al. 89Zr-bevacizumab PET imaging in primary breast cancer. J Nucl Med 2013;54:1014–8.
- 16 Nagengast WB, de Korte MA, Oude Munnink TH, et al. 89Zr-bevacizumab PET of early antiangiogenic tumor response to treatment with HSP90 inhibitor NVP-AUY922. J Nucl Med 2010;51:761–7.
- 17 Nagengast WB, de Vries EG, Hospers GA, et al. In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft. J Nucl Med 2007;48:1313–9.
- 18 Griffiths EA, Pritchard SA, McGrath SM, et al. Increasing expression of hypoxiainducible proteins in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence. Br J Cancer 2007;96:1377–83.
- 19 Möbius C, Stein HJ, Becker I, et al. The 'angiogenic switch' in the progression from Barrett's metaplasia to esophageal adenocarcinoma. Eur J Surg Oncol 2003;29:890–4.
- 20 Folkman J, Watson K, Ingber D, et al. Induction of angiogenesis during the transition from hyperplasia to neoplasia. *Nature* 1989;339:58–61.
- 21 Auvinen MI, Sihvo EI, Ruohtula T, et al. Incipient angiogenesis in Barrett's epithelium and lymphangiogenesis in Barrett's adenocarcinoma. J Clin Oncol 2002;20:2971–9.
- 22 Kleespies A, Guba M, Jauch K-W, et al. Vascular endothelial growth factor in esophageal cancer. J Surg Oncol 2004;87:95–104.